^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor) +
    Opdivo (nivolumab) (PD1 inhibitor) +
    Imbruvica (ibrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Nivolumab and pembrolizumab ± ibrutinib are included as options with a category 2B recommendation for patients unable to receive chemoimmunotherapy, patients with del (17p) or TP53 mutation, or those with chemoimmunotherapy-refractory disease.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EHA 2020
    Title:

    BASELINE TP53 MUTATIONS AND MOLECULAR REMISSION ARE BIOMARKERS OF RESPONSE TO TREATMENT WITH IBRUTINIB PLUS NIVOLUMAB IN RELAPSED/REFRACTORY DLBCL

    Published date:
    06/12/2020
    Excerpt:
    After considering genes mutated in > 10% of cases, only TP53 mutation status was significantly associated with inferior progression-free survival (PFS; 12-month PFS of 0% in TP53 mutated cases vs 53.6% in TP53 wild type cases; p = 0.002) (Figure A).
    Trial ID:
    NCT02329847